The formulation and evaluation of mouth dissolving tablet Levocetirizine by using synthetic Superdisintegrants
Aim of this research work was to develop mouth dissolving tablet that disintegrates rapidly in mouth by using tasteless complex of Levocetirizine and β-CD. Mouth dissolving Tablets also called as Orodispersible tablets. Formulated Levocetirizine β-CD complex was characterized by infrared spectroscopy, thermal analysis and X-ray diffraction pattern. Tablets were developed by direct compression method. Superdisintegrants like Sodium starch glycolate (SSG), Crosscarmellose sodium (CCS) and Crosspovidone (CP) were used for the formulation. Every formulation was subjected to in-vitro tests like wetting time, disintegration test and dissolution test. The in-vitro study showed that increasing the concentration of superdisintegrants lowers the wetting time (WT) and disintegration time (DT) and enhances the drug release percentage of the formulations.
The formulation CPX5 was the most effective formulation as it showed wetting time of 12 seconds, disintegration time of 20 seconds and cumulative % drug release of 41 and 99% at 1 and 10 minutes respectively. The study showed that the formulations containing SSG and CP as the superdisintegrants showed better drug release pattern than the formulations with other superdisintegrants. The study also showed that SSG as the superdisintegrant was more effective for the formulation of orodispersible tablets of levocetirizine dihydrochloride
2. Sahoo S, Mishra B, Biswal PK, Panda Omprakash, Mahapatra K Santosh, Jana K Goutam. Vol. 2. Fast Dissolving Tablet: As A Potential Drug Delivery System. Drug Inv. Today; 2010.
3. Kaur et al., Vol. 3. Mouth dissolving tablets: A novel approach to drug delivery, International Journal of Current Pharmaceutical Research; 2011 .p. 1-7.
4. Nayak UK., Patra SK., Rout PK., Patro BK. and Nayak BS. Development and optimization of promethazine theoclate Mouth dissolving tablets; The Indian pharmacist; 2008 .p. 65- 68.
5. Seager H. Vol. 50. Drug-delivery Products and the Zydis Fast-dissolving Dosage Form. J Pharm Pharmacol; 1998 .p. 375-382.
6. Bradoo R, Shahani S, Poojary S, Deewan B, Sudarshan S. Vol. 4 No. 10. Fast Dissolving Drug Delivery Systems. JAMA India; 2001 .p. 27-31.
7. Voleti VK; Gunasekharan V; Bolla SP; Kumar JM; Rayaprolu M; Vol. 5 No. 4. Formulation and evaluation of levociterizine dihydrochloride fast dissolving tablets using superdisintegrants. International Journel of Pharmacy and Pharmaceutical Sciences; 2013 .p. 324-28.
8. Dobetti L. Fast melting tablets: Development and technology. Pharm Tech Drug Delivery; 2001 .p. 44-50.
9. Bi Y, Sunada H, Yonezawa Y, Danjo K, Iida K. Vol. 44 Preparation and evaluation of compressed tablets rapidly disintegrating in the oral cavity. Chem Pharm Bull (Tokyo); 1996 .p.2121-27.
10. Andries F. Marais, Mingna Song, Melgardt M. de Villiers. Vol. 2 No. 1 Effect of compression force, humidity and disintegrant concentration on the disintegration and dissolution of directly.Tropical Journal of Pharmaceutical Research; 2003 .p. 125-35.
11. Shenoy V, Agrawal S, Pandey S. Vol. 65 No. 2. Optimizing fast dissolving Dosage form of Diclofenac Sodium by rapidly disintegrating agents. Indian J Pharm Sci; 2003 .p. 197-201.
12. Jones RJ, Ali RS, Marina L, Perrie Y, Afzal MR. Vol. 3. The influence of formulation and manufacturing process parameters on the characteristics of lyophilized orally disintegrating tablets. Pharmaceutics; 2011 .p. 440-57.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Innovative Science & Technology affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJIST.
Download link for COPYRIGHT FORM